Zivo Bioscience annual stock-based compensation
2017
2018
2019
2020
2021
2022
2023
2024
Zivo Bioscience Stock-Based Compensation Growth & History (ZIVO)
Zivo Bioscience's stock-based compensation was $1.5M for fiscal 2024.
View full Zivo Bioscience company overviewZivo Bioscience annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $1.5M | $1.4M | +1588.33% |
| 2023 | 2023-12-31 | $89,502 | $387,155 | — |
| 2022 | 2022-12-31 | −$297,653 | −$193,052 | — |
| 2021 | 2021-12-31 | −$104,601 | −$1.4M | — |
| 2020 | 2020-12-31 | $1.2M | −$2.4M | −65.37% |
| 2019 | 2019-12-31 | $3.6M | $3.5M | +4019.89% |
| 2018 | 2018-12-31 | $87,508 | −$2.4M | −96.48% |
| 2017 | 2017-12-31 | $2.5M | — | — |
Zivo Bioscience quarterly stock-based compensation
Q3.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q2.23
Q3.23
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | $26,959 | — | — |
| Q2 2025 | 2025-06-30 | $336,743 | — | — |
| Q1 2025 | 2025-03-31 | $600,545 | — | — |
| Q4 2024 | 2024-12-31 | $745,086 | — | — |
| Q3 2023 | 2023-09-30 | $240,750 | −$277,411 | −53.54% |
| Q2 2023 | 2023-06-30 | $227,808 | −$269,936 | −54.23% |
| Q3 2022 | 2022-09-30 | $518,161 | $293,955 | +131.11% |
| Q2 2022 | 2022-06-30 | $497,744 | $105,379 | +26.86% |
| Q1 2022 | 2022-03-31 | $570,629 | −$404,395 | −41.48% |
| Q3 2021 | 2021-09-30 | $224,206 | −$1.7M | −88.57% |
| Q2 2021 | 2021-06-30 | $392,365 | $392,365 | — |
| Q1 2021 | 2021-03-31 | $975,024 | −$221,198 | −18.49% |
| Q3 2020 | 2020-09-30 | $2.0M | $1.5M | +359.01% |
| Q2 2020 | 2020-06-30 | $0 | −$533,823 | — |
| Q1 2020 | 2020-03-31 | $1.2M | $1.2M | +4780.15% |
| Q4 2019 | 2019-12-31 | $2.6M | — | — |
| Q3 2019 | 2019-09-30 | $427,497 | −$3,591 | −0.83% |
| Q2 2019 | 2019-06-30 | $533,823 | $278,430 | +109.02% |
| Q1 2019 | 2019-03-31 | $24,512 | −$258,828 | −91.35% |
| Q3 2018 | 2018-09-30 | $431,088 | −$826,264 | −65.71% |
| Q2 2018 | 2018-06-30 | $255,393 | $195,347 | +325.33% |
| Q1 2018 | 2018-03-31 | $283,340 | $263,449 | +1324.46% |
| Q4 2017 | 2017-12-31 | $1.2M | — | — |
| Q3 2017 | 2017-09-30 | $1.3M | $1.2M | +1914.02% |
| Q2 2017 | 2017-06-30 | $60,046 | — | — |
| Q1 2017 | 2017-03-31 | $19,891 | — | — |
| Q3 2016 | 2016-09-30 | $62,430 | — | — |
Zivo Bioscience stock-based compensation trends
Over the last five fiscal years, Zivo Bioscience's stock-based compensation decreased from $3.6M to $1.5M, a change of −$2.1M. The latest reported quarter, Q3 2025, shows $26,959.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zivo Bioscience source filings ↗